List of Excipients in Branded Drug NITRO-DUR

« Back to Dashboard

NITRO-DUR Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

Nitro-Dur is a nitroglycerin transdermal delivery system for the prevention of angina pectoris. Its commercial value is tied less to nitroglycerin itself, an established generic active ingredient, and more to patch engineering: dose-rate control, skin permeation, adhesion, stability, residual drug content, and manufacturing consistency. The strongest opportunities are generic or improved transdermal systems that solve adhesion, irritation, wear-time, and dose-uniformity problems while maintaining the established nitrate-free interval required to limit tolerance.

What is Nitro-Dur and how does its delivery system work?

Nitro-Dur delivers nitroglycerin through the skin at nominal rates commonly identified as 0.1, 0.2, 0.3, 0.4, and 0.6 mg per hour. The product is applied once daily, with the transdermal system removed for approximately 10 to 12 hours to reduce nitrate tolerance. The FDA label identifies Nitro-Dur as a transdermal system rather than an oral dosage form or conventional topical cream. [1]

The commercial performance of the product depends on the entire patch architecture:

Product attribute	Commercial function	Excipient or component relevance
Drug-in-adhesive or matrix layer	Holds nitroglycerin and controls release	Acrylic, silicone, or related pressure-sensitive adhesive systems
Backing layer	Limits drug loss and protects the patch	Polymeric film with controlled moisture and oxygen transmission
Release liner	Protects the adhesive before use	Silicone-coated polyester or comparable liner
Permeation interface	Controls delivery into skin	Adhesive chemistry, drug solubilization, and skin-contact area
Drug loading	Establishes delivery duration	Nitroglycerin concentration, crystallization control, and residual content
Skin adhesion	Maintains contact during daily use	Tack, shear strength, peel strength, and resistance to sweat
Packaging	Protects a chemically sensitive nitrate	High-barrier pouch, seal integrity, and light protection

Nitroglycerin is volatile and chemically sensitive. Packaging, adhesive selection, manufacturing temperature, and residual solvent control can affect potency and shelf life. A formulation that delivers the nominal dose in laboratory testing but loses nitroglycerin during storage will not be commercially viable.

What excipients and patch materials are used in Nitro-Dur?

Nitro-Dur labeling describes a multilayer transdermal system containing nitroglycerin in an adhesive-based delivery structure. Public product labeling does not provide the full quantitative composition of every proprietary layer. [1] That limits direct formula copying and shifts generic-development work toward pharmaceutical equivalence, performance testing, and reverse engineering.

The key excipient categories are:

Pressure-sensitive adhesive

The adhesive is the primary formulation platform in a drug-in-adhesive patch. It must hold nitroglycerin in a stable, non-crystallizing state and maintain skin contact throughout the labeled wear period.

Potential systems include:

• Acrylic adhesives
• Silicone adhesives
• Polyisobutylene-based systems
• Blended adhesive systems with tackifiers or plasticizers

Acrylic systems can offer strong adhesion and broad formulation flexibility but may increase skin irritation risk if residual monomers or sensitizing components are not controlled. Silicone systems often have favorable skin tolerability and good release characteristics but can present challenges in drug solubilization, coat weight, and cost.

Solubilizers and crystallization-control agents

Nitroglycerin must remain uniformly distributed within the adhesive or matrix. A formulation that permits crystallization can create dose nonuniformity, altered release, and reduced skin flux.

Possible development tools include:

• Compatible plasticizers
• Co-solvents
• Polymer modifiers
• Low-volatility solubilizers
• Drug-loading limits that preserve supersaturation control

The preferred excipient is not necessarily the one that maximizes initial drug loading. The relevant metric is stable delivery over shelf life and the intended wear interval.

Backing and release-liner materials

Backing films influence moisture exchange, oxygen exposure, handling, and drug retention. A poorly selected backing can cause drug loss through evaporation or destabilize the adhesive.

The release liner must remove cleanly without stripping adhesive from the patch or disturbing the drug layer. Silicone-coated films are common in transdermal systems, but liner selection affects manufacturing speed, die cutting, peel force, and patient usability.

Stabilization and packaging

Nitroglycerin products require tight control of packaging conditions. A high-barrier pouch can be as important as the formulation itself. Development should evaluate:

• Nitroglycerin assay over shelf life
• Degradation products
• Evaporative loss
• Pouch moisture and oxygen transmission
• Seal integrity
• Light exposure
• Temperature excursions
• Drug transfer to packaging surfaces

USP performance testing and FDA transdermal-product guidance support evaluation of adhesion, release, permeation, product quality, and stability. [2,3]

What excipient strategy is strongest for a Nitro-Dur generic?

A conventional acrylic drug-in-adhesive system is the most direct development route if the reference product can be adequately characterized. It may offer lower manufacturing complexity than a reservoir system and can support multiple dose strengths by changing patch area or drug loading.

A silicone drug-in-adhesive system offers a potential differentiation path where the reference product has adhesion or irritation limitations. Silicone systems can support improved skin tolerability, although the sponsor must establish equivalent delivery and avoid excessive residual drug.

A multilayer matrix system may provide better control of drug distribution and mechanical properties. Its development burden is higher because manufacturing must maintain layer uniformity, interfacial integrity, and consistent drug release.

Strategy	Development burden	Main advantage	Principal risk
Acrylic drug-in-adhesive	Low to moderate	Direct generic pathway and scalable coating	Irritation, crystallization, variable adhesion
Silicone drug-in-adhesive	Moderate	Potential tolerability and adhesion differentiation	Drug solubility and cost
Polyisobutylene matrix	Moderate	Established transdermal platform	Limited formulation flexibility
Multilayer matrix	High	Better physical and release control	More complex manufacturing and equivalence testing
Microneedle or enhanced-permeation system	Very high	Potentially shorter wear time or lower dose	New-device and clinical-development burden

The highest probability strategy is a stable, low-irritation drug-in-adhesive patch with reliable adhesion during sweating and movement. A technically novel platform is less attractive unless it produces a meaningful clinical or commercial benefit.

What patents protect Nitro-Dur and its excipient platform?

The original Nitro-Dur product and early nitroglycerin transdermal patents date from the early transdermal-product era. Those foundational patents would generally be expected to have expired after the standard U.S. patent term, subject to patent-specific filing dates, patent-term adjustments, and any applicable extensions.

The active ingredient, nitroglycerin, is not a meaningful composition-of-matter barrier. Any residual exclusivity risk would more likely involve:

• Product-specific formulation patents
• Adhesive or matrix architecture
• Manufacturing methods
• Packaging systems
• Device or applicator claims
• Method-of-use claims
• Later-listed patents associated with a particular approved product

The FDA Orange Book is the controlling source for current listed patents and regulatory exclusivity associated with an approved drug product. [4] A generic sponsor should separately review the current Orange Book entry, FDA approval history, listed patents, patent-term data, and litigation docket before selecting an ANDA certification strategy.

Are there biosimilar risks for Nitro-Dur?

No. Nitro-Dur contains nitroglycerin, a chemically synthesized small molecule. Biosimilar regulation under the Public Health Service Act does not apply. Competition proceeds through generic-drug pathways, primarily an ANDA demonstrating pharmaceutical equivalence and bioequivalence or other FDA-accepted product-specific evidence.

When does Nitro-Dur lose exclusivity?

The original regulatory and patent barriers for Nitro-Dur are historical rather than emerging. Nitro-Dur is not a newly protected product, and generic nitroglycerin transdermal systems have been commercially developed. The practical question is therefore not the date of initial loss of exclusivity but whether any current listed patents, market discontinuity, manufacturing constraints, or regulatory differences limit substitution.

FDA exclusivity and patent analysis should distinguish:

Barrier	Relevance to Nitro-Dur
New chemical entity exclusivity	No practical relevance for an old nitroglycerin product
Orphan-drug exclusivity	Not the standard basis for Nitro-Dur protection
Pediatric exclusivity	Must be checked in current FDA records, but not normally the central barrier
Formulation patent	Potentially relevant if currently listed
Method-of-use patent	Relevant only if listed and applicable to the proposed label
Device patent	Relevant if the patch architecture or delivery device is claimed
Manufacturing patent	May affect freedom to operate without blocking FDA approval
Trade secret	Can impede reverse engineering or manufacturing scale-up without creating Orange Book exclusivity

What FDA regulatory pathway applies to Nitro-Dur competitors?

A conventional nitroglycerin patch is generally a small-molecule generic product. An ANDA sponsor must establish sameness or acceptable equivalence in the relevant product characteristics, including dosage form, strength, route of administration, and performance.

Transdermal products can face more demanding development issues than simple oral solids. Key evidence may include:

• Comparative assay and content uniformity
• In vitro drug release
• Adhesion performance
• Skin permeation
• Adhesive-residue assessment
• Stability data
• Packaging qualification
• Local irritation or sensitization assessment
• Pharmacokinetic comparison where required

FDA guidance recognizes that transdermal and topical delivery systems require product-specific evaluation rather than reliance on a single conventional dissolution test. [2,3]

What commercial opportunities exist for Nitro-Dur excipients?

The opportunity is broader than supplying a single adhesive. Excipient and component suppliers can target the full transdermal manufacturing chain.

Improved skin adhesion

Patches can lose contact because of sweat, body movement, body hair, or repeated friction. A supplier that provides a high-tack adhesive without excessive irritation can compete on a measurable performance attribute.

Potential claims include:

• Longer continuous wear
• Lower edge lift
• Improved adhesion in humid conditions
• Reduced residue after removal
• Better adhesion across skin types

These claims require product-specific testing and cannot be treated as automatic benefits of a particular polymer.

Lower irritation and sensitization

Nitroglycerin patches are used repeatedly. Skin tolerability is therefore commercially important. Opportunities include low-irritation acrylics, silicone adhesives, and formulations that reduce solvent residues or sensitizing impurities.

A formulation change that improves tolerability but alters nitroglycerin flux can create a regulatory problem. Adhesive optimization must be paired with permeation and pharmacokinetic testing.

High-barrier packaging

Packaging suppliers can differentiate through improved control of nitroglycerin loss, moisture ingress, and oxygen exposure. The opportunity is strongest where a manufacturer seeks longer shelf life, better temperature-excursion performance, or reduced batch rejection.

Manufacturing platforms

Contract development and manufacturing organizations can offer:

• Continuous adhesive coating
• Precision die cutting
• In-line coat-weight measurement
• Pouching and nitrogen or controlled-atmosphere packaging
• Automated inspection for wrinkles, voids, and edge defects
• Stability-indicating analytical methods

Manufacturing capability is a meaningful barrier because transdermal products require tight control of coat weight, drug distribution, and patch dimensions.

Which Nitro-Dur product extensions have commercial potential?

The most credible extensions are incremental rather than radical.

Product concept	Commercial rationale	Regulatory complexity
Lower-cost generic patch	Price competition and supply continuity	Moderate
Improved-adhesion patch	Addresses wear failure	Moderate to high
Lower-irritation patch	Supports chronic intermittent use	Moderate to high
Smaller patch with equivalent delivery	Improves convenience	High
Extended-wear patch	Reduces application burden	High
Combination cardiovascular patch	Broadens therapy but increases risk	Very high
Digital adherence-enabled package	Tracks application and removal	Moderate to high
Non-patch nitroglycerin delivery system	Differentiates route or convenience	High

An extended-wear product must preserve the nitrate-free interval. A patch that remains on the skin longer than the established regimen could increase tolerance and undermine the therapeutic rationale. Any extension therefore requires clinical and regulatory justification.

What generic launch risks exist for Nitro-Dur?

The principal risks are technical and commercial:

1. Adhesion failure. A patch that detaches early can produce underdelivery and poor patient acceptance.
2. Dose-rate variability. Small changes in coat weight or adhesive composition can alter delivery.
3. Nitroglycerin instability. Volatility and degradation can reduce shelf-life performance.
4. Skin irritation. Repeated exposure increases the commercial impact of dermatitis.
5. Reference-product discontinuity. A discontinued or supply-constrained reference product can complicate comparative testing and market access.
6. Limited market size. Chronic angina treatment has shifted toward oral antianginals, revascularization, and other cardiovascular therapies, limiting total patch demand.
7. Price erosion. Multiple generic entrants can reduce margins rapidly.
8. Manufacturing scale-up. Laboratory coating performance may not translate to commercial roll-to-roll production.

How strong is the Nitro-Dur patent estate?

The legacy patent estate is likely weak as a barrier to ordinary generic entry because nitroglycerin transdermal delivery is an old technology and the original product has long been marketed. The meaningful freedom-to-operate analysis remains claim-specific and product-specific.

A sponsor should focus on current Orange Book listings, active formulation claims, manufacturing patents, and third-party adhesive patents. A design-around using a different adhesive family, backing film, liner, or coating process may reduce infringement exposure while preserving the same therapeutic product concept.

What licensing opportunities exist?

Licensing value is most likely to arise from enabling technology rather than Nitro-Dur brand rights. Relevant assets include:

• Low-irritation pressure-sensitive adhesives
• Nitroglycerin-stabilizing excipient systems
• High-barrier pouch technology
• Transdermal coating and inspection processes
• Skin-permeation models
• Patch-construction patents
• Regional marketing rights for generic transdermal products

A licensing agreement should allocate responsibility for FDA correspondence, stability failures, field complaints, adhesive performance, product recalls, patent indemnity, and supply continuity. Royalty economics are likely to be constrained by generic price erosion unless the licensed technology solves a documented manufacturing or clinical-use problem.

Key Takeaways

• Nitro-Dur is a nitroglycerin transdermal system whose value is concentrated in patch engineering rather than active-ingredient exclusivity.
• The key excipient decisions concern adhesive chemistry, nitroglycerin solubilization, crystallization control, backing films, release liners, and high-barrier packaging.
• A stable drug-in-adhesive generic is the most practical development route.
• Biosimilar competition is irrelevant because nitroglycerin is a small molecule.
• Foundational Nitro-Dur patent protection is historical; current Orange Book and freedom-to-operate reviews remain necessary for any specific launch.
• The strongest commercial opportunities are improved adhesion, lower skin irritation, better packaging stability, and reliable manufacturing.
• Extended-wear products face a clinical and regulatory constraint because nitrate-free intervals are central to limiting tolerance.
• Generic launch economics are exposed to technical scale-up risk, limited market growth, and price erosion.

FAQs

Can a new Nitro-Dur patch use a different adhesive?

Yes. A different adhesive may be used if the product meets FDA requirements for pharmaceutical equivalence, performance, stability, safety, and bioequivalence or other applicable evidence. The change can create both a design-around opportunity and a new formulation-development burden.

Is nitroglycerin itself patentable in a new Nitro-Dur formulation?

A new formulation may support patent protection if it has novel, non-obvious, and adequately disclosed features. Nitroglycerin as an old active ingredient does not provide meaningful new chemical entity protection.

Can a Nitro-Dur generic have a different patch size?

Potentially, but patch area affects drug loading, delivery rate, adhesion, and patient handling. A different size requires comparative performance and regulatory support.

Are silicone adhesives commercially attractive for nitroglycerin patches?

They can be attractive where skin tolerability and clean removal are priorities. Their suitability depends on nitroglycerin solubility, release behavior, coatability, and manufacturing cost.

Does Nitro-Dur require a new clinical trial for every excipient change?

Not necessarily. The required evidence depends on the nature and extent of the change, the regulatory pathway, and the effect on product performance. Transdermal changes can require more extensive comparative testing than conventional inactive-ingredient substitutions.

References

1. U.S. Food and Drug Administration. (2008). Nitro-Dur nitroglycerin transdermal system: Prescribing information.
2. U.S. Food and Drug Administration. (1997). Guidance for industry: SUPAC-SS, nonsterile semisolid dosage forms scale-up and postapproval changes.
3. U.S. Food and Drug Administration. (2019). Transdermal and topical delivery systems: Product development and quality considerations: Draft guidance for industry.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. Washington, DC.